Atanasio Gómez-Mulas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Atanasio Gómez-Mulas has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Abankwa
University of Luxembourg
4 shared publications - Elisabeth Schaffner-Reckinger
Cancer Cell Biology and Drug Discovery group, Department of Health, Medicine and Life Sciences, University of Luxembourg, Esch-sur-Alzette, Luxembourg
4 shared publications - Rohan Chippalkatti
Cancer Cell Biology and Drug Discovery group, Department of Health, Medicine and Life Sciences, University of Luxembourg, L-4365 Esch-sur-Alzette, Luxembourg
4 shared publications - Bianca Parisi
Cancer Cell Biology and Drug Discovery group, Department of Health, Medicine and Life Sciences, University of Luxembourg, L-4365 Esch-sur-Alzette, Luxembourg
2 shared publications Christina Laurini
Cancer Cell Biology and Drug Discovery group, Department of Health, Medicine and Life Sciences, University of Luxembourg, L-4365 Esch-sur-Alzette, Luxembourg
2 shared publications- Hanne Peeters
The Mechanistic Molecular Biochemistry Group Department of Chemistry KU Leuven Celestijnenlaan 200G 3001 Heverlee Belgium
2 shared publications
Latest Publications
- Open Access
Regulation of de- and reciliation by KRAS during muscle cell differentiation
Summary: The primary cilium has been implicated in multiple developmental processes, such as cell migration and asymmetric cell division of stem- and progenitor cells. While most in vitro model systems examine ciliogenesis induced by serum starvation, it is not fully understood how de-and re-ciliation are regulated in proliferating stem- and progenitor cells. Here we employ the hierarchically organized C2C12 skeletal muscle cell line to examine how K-Ras4B participates in de- and re-ciliation processes of ciliated stem- and progenitor cells. We show that MAPK-pathway activation supports ciliogenesis through phosphorylation of centrosomal protein CEP55, which can then no longer stabilize the master regulator of de-ciliation Aurora kinase A. K-Ras4B localizes to the primary cilium aided by the ciliary trafficking chaperone PDE6D, which promotes ciliation. In line with this, depletion of components of the PDE6D machinery, RPGR and RPGRIP1L, decreases ciliation. Activation of the ciliary AMPK-PKG2-pathway increases S181-phosphorylation of K-Ras4B, which negatively regulates its binding to PDE6D, its ciliary abundance and promotes differentiation. Our work integrates a major mediator of mitogenic signaling into the regulation of ciliogenesis of proliferating muscle stem- and progenitor cells.
Open AccessRegulation of de- and reciliation by KRAS during muscle cell differentiation
Summary: The primary cilium has been implicated in multiple developmental processes, such as cell migration and asymmetric cell division of stem- and progenitor cells. While most in vitro model systems examine ciliogenesis induced by serum starvation, it is not fully understood how de-and re-ciliation are regulated in proliferating stem- and progenitor cells. Here we employ the hierarchically organized C2C12 skeletal muscle cell line to examine how K-Ras4B participates in de- and re-ciliation processes of ciliated stem- and progenitor cells. We show that MAPK-pathway activation supports ciliogenesis through phosphorylation of centrosomal protein CEP55, which can then no longer stabilize the master regulator of de-ciliation Aurora kinase A. K-Ras4B localizes to the primary cilium aided by the ciliary trafficking chaperone PDE6D, which promotes ciliation. In line with this, depletion of components of the PDE6D machinery, RPGR and RPGRIP1L, decreases ciliation. Activation of the ciliary AMPK-PKG2-pathway increases S181-phosphorylation of K-Ras4B, which negatively regulates its binding to PDE6D, its ciliary abundance and promotes differentiation. Our work integrates a major mediator of mitogenic signaling into the regulation of ciliogenesis of proliferating muscle stem- and progenitor cells.
- Open Access
K-Ras controls asymmetric cell divisions from the primary cilium
The Ras-MAPK pathway drives central cellular processes, including cell proliferation and differentiation. How exactly Ras controls differentiation is however not understood. Supported by mathematical modelling and single-cell RNA sequencing we show that K-Ras4B sustains ciliation during differentiation thus restricting commitment of skeletal muscle stem and progenitor cells during asymmetric cell divisions. Modulation of K-Ras4B abundance or expression of oncogenic K-Ras4B-G12C perturb normal differentiation. K-Ras4B, but not N-Ras and H-Ras, localizes to the primary cilium and its abundance there depends on the ciliary trafficking chaperone PDE6D. The presence of B-Raf and active MEK at the base of and active ERK inside the cilium suggests that K-Ras4B is active there. Conditions that localize a K-Ras4B mutant only to the cilium are sufficient to sustain ciliation and normal differentiation. Finally, in vivo modulation of K-Ras4B activity during zebrafish embryogenesis perturbs ciliation-dependent heart-looping. Our results thus imply a novel fundamental role of K-Ras4B in controlling ciliation and differentiation and suggest an explanation for the phenotypic similarities between RASopathies and ciliopathies.
Open AccessK-Ras controls asymmetric cell divisions from the primary cilium
The Ras-MAPK pathway drives central cellular processes, including cell proliferation and differentiation. How exactly Ras controls differentiation is however not understood. Supported by mathematical modelling and single-cell RNA sequencing we show that K-Ras4B sustains ciliation during differentiation thus restricting commitment of skeletal muscle stem and progenitor cells during asymmetric cell divisions. Modulation of K-Ras4B abundance or expression of oncogenic K-Ras4B-G12C perturb normal differentiation. K-Ras4B, but not N-Ras and H-Ras, localizes to the primary cilium and its abundance there depends on the ciliary trafficking chaperone PDE6D. The presence of B-Raf and active MEK at the base of and active ERK inside the cilium suggests that K-Ras4B is active there. Conditions that localize a K-Ras4B mutant only to the cilium are sufficient to sustain ciliation and normal differentiation. Finally, in vivo modulation of K-Ras4B activity during zebrafish embryogenesis perturbs ciliation-dependent heart-looping. Our results thus imply a novel fundamental role of K-Ras4B in controlling ciliation and differentiation and suggest an explanation for the phenotypic similarities between RASopathies and ciliopathies.
- Open Access
- 18 November 2025
- Published by Wiley in ChemBioChem
- Vol. 26 (24) , e202500739
Development of a Genetically Encoded and Potent PDE6D Inhibitor
PDE6D is a trafficking chaperone of prenylated proteins, such as small GTPases. Several small molecule inhibitors have been developed against it, given that the oncogene K‐Ras is one of the cargo proteins. Inhibitor development suffers from the fact that inhibitors against the hydrophobic pocket of PDE6D are typically poorly water‐soluble. Herein, the development of genetically encoded inhibitors that are inspired by high‐affinity natural cargo of PDE6D is described. The most potent inhibitor, SNAP‐STI, encodes merely a farnesylated tetra‐peptide, which efficiently blocks PDE6D binding of farnesylated cargo. Direct comparison with small molecule PDE6D inhibitors suggests its higher potency. It is shown that inhibition of K‐Ras membrane anchorage and K‐RasG12C‐dependent MAPK signaling by SNAP‐STI is weak, consistent with what is observed after PDE6D knockdown. The data therefore further support that PDE6D is not a suitable surrogate target for efficient inhibition of K‐Ras membrane anchorage and MAPK‐activity. Nonetheless, by exploiting contacts at the pocket entry, a generalizable strategy to design high‐affinity PDE6D inhibitors is established, providing powerful tools for PDE6D biology and target validation.
- 18 November 2025
- Published by Wiley in ChemBioChem
- Vol. 26 (24) , e202500739
Open AccessDevelopment of a Genetically Encoded and Potent PDE6D Inhibitor
PDE6D is a trafficking chaperone of prenylated proteins, such as small GTPases. Several small molecule inhibitors have been developed against it, given that the oncogene K‐Ras is one of the cargo proteins. Inhibitor development suffers from the fact that inhibitors against the hydrophobic pocket of PDE6D are typically poorly water‐soluble. Herein, the development of genetically encoded inhibitors that are inspired by high‐affinity natural cargo of PDE6D is described. The most potent inhibitor, SNAP‐STI, encodes merely a farnesylated tetra‐peptide, which efficiently blocks PDE6D binding of farnesylated cargo. Direct comparison with small molecule PDE6D inhibitors suggests its higher potency. It is shown that inhibition of K‐Ras membrane anchorage and K‐RasG12C‐dependent MAPK signaling by SNAP‐STI is weak, consistent with what is observed after PDE6D knockdown. The data therefore further support that PDE6D is not a suitable surrogate target for efficient inhibition of K‐Ras membrane anchorage and MAPK‐activity. Nonetheless, by exploiting contacts at the pocket entry, a generalizable strategy to design high‐affinity PDE6D inhibitors is established, providing powerful tools for PDE6D biology and target validation.
- Open Access
Development of a genetically encoded and potent PDE6D inhibitor
PDE6D is a trafficking chaperone of prenylated proteins, such as small GTPases. Several small molecule inhibitors have been developed against it, given that the oncogene K-Ras is one of the cargo proteins. Inhibitor development suffered from the fact that inhibitors against the hydrophobic pocket of PDE6D were typically poorly water-soluble. Here we describe the development of genetically encoded inhibitors that are inspired by high-affinity natural cargo of PDE6D. Our most potent inhibitor, SNAP-STI, encodes merely a farnesylated tetra-peptide, which efficiently blocks PDE6D binding of farnesylated cargo. Direct comparison with small molecule PDE6D inhibitors suggests its higher potency. We show that inhibition of K-Ras membrane anchorage and K-RasG12C-dependent MAPK-signaling by SNAP-STI is weak, consistent with what is observed after PDE6D knockdown. Our data therefore further support that PDE6D is not a suitable surrogate target for efficient inhibition of K-Ras membrane anchorage and MAPK-activity. Nonetheless, by exploiting contacts at the pocket entry, we established a generalizable strategy to design high-affinity PDE6D inhibitors, providing powerful tools for PDE6D biology and target validation.
Open AccessDevelopment of a genetically encoded and potent PDE6D inhibitor
PDE6D is a trafficking chaperone of prenylated proteins, such as small GTPases. Several small molecule inhibitors have been developed against it, given that the oncogene K-Ras is one of the cargo proteins. Inhibitor development suffered from the fact that inhibitors against the hydrophobic pocket of PDE6D were typically poorly water-soluble. Here we describe the development of genetically encoded inhibitors that are inspired by high-affinity natural cargo of PDE6D. Our most potent inhibitor, SNAP-STI, encodes merely a farnesylated tetra-peptide, which efficiently blocks PDE6D binding of farnesylated cargo. Direct comparison with small molecule PDE6D inhibitors suggests its higher potency. We show that inhibition of K-Ras membrane anchorage and K-RasG12C-dependent MAPK-signaling by SNAP-STI is weak, consistent with what is observed after PDE6D knockdown. Our data therefore further support that PDE6D is not a suitable surrogate target for efficient inhibition of K-Ras membrane anchorage and MAPK-activity. Nonetheless, by exploiting contacts at the pocket entry, we established a generalizable strategy to design high-affinity PDE6D inhibitors, providing powerful tools for PDE6D biology and target validation.